Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
25.29
-0.48 (-1.86%)
At close: Dec 18, 2025, 4:00 PM EST
25.29
0.00 (0.00%)
Pre-market: Dec 19, 2025, 4:13 AM EST
Celldex Therapeutics Revenue
Celldex Therapeutics had revenue of $2.60M in the twelve months ending September 30, 2025, down -73.94% year-over-year. In the year 2024, Celldex Therapeutics had annual revenue of $7.02M with 1.99% growth.
Revenue (ttm)
$2.60M
Revenue Growth
-73.94%
P/S Ratio
646.60
Revenue / Employee
$13,973
Employees
186
Market Cap
1.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.02M | 137.00K | 1.99% |
| Dec 31, 2023 | 6.88M | 4.53M | 192.02% |
| Dec 31, 2022 | 2.36M | -2.29M | -49.32% |
| Dec 31, 2021 | 4.65M | -2.77M | -37.30% |
| Dec 31, 2020 | 7.42M | 3.85M | 107.61% |
| Dec 31, 2019 | 3.57M | -5.97M | -62.54% |
| Dec 31, 2018 | 9.54M | -3.21M | -25.15% |
| Dec 31, 2017 | 12.74M | 5.96M | 87.78% |
| Dec 31, 2016 | 6.79M | 1.31M | 23.83% |
| Dec 31, 2015 | 5.48M | 1.89M | 52.82% |
| Dec 31, 2014 | 3.59M | -525.00K | -12.77% |
| Dec 31, 2013 | 4.11M | -7.09M | -63.30% |
| Dec 31, 2012 | 11.20M | 1.94M | 20.91% |
| Dec 31, 2011 | 9.27M | -37.53M | -80.20% |
| Dec 31, 2010 | 46.79M | 31.61M | 208.25% |
| Dec 31, 2009 | 15.18M | 7.72M | 103.59% |
| Dec 31, 2008 | 7.46M | 6.05M | 430.30% |
| Dec 31, 2007 | 1.41M | 506.82K | 56.36% |
| Dec 31, 2006 | 899.18K | -2.19M | -70.88% |
| Dec 31, 2005 | 3.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CLDX News
- 9 days ago - Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism - GlobeNewsWire
- 5 weeks ago - Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer - GlobeNewsWire
- 5 weeks ago - Celldex to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 - GlobeNewsWire
- 3 months ago - Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 4 months ago - Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track - Seeking Alpha
- 4 months ago - Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short - Benzinga